Paratek Pharmaceuticals, Inc. (PRTK)
| Previous Close | 1.9600 |
| Open | 1.9300 |
| Bid | 1.9200 x 900 |
| Ask | 1.9300 x 1200 |
| Day's Range | 1.8450 - 2.0150 |
| 52 Week Range | 1.7900 - 11.2400 |
| Volume | |
| Avg. Volume | 555,729 |
| Market Cap | 94.355M |
| Beta (5Y Monthly) | 1.50 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Oct 31, 2014 |
| 1y Target Est | N/A |
- GlobeNewswire
Paratek Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that Evan Loh, M.D., chief executive officer, will participate in a virtual fireside chat during the H.C. Wainwright Global Investment Conference. The conference will b
- GlobeNewswire
Paratek Pharmaceuticals Announces First Quarter 2022 Revenue of $24.9 Million
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.9 Million from the Core Commercial Business, a 51% Increase over First Quarter 2021 -- Omadacycline Demonstrated Potent In Vitro Efficacy Against Mycobacterium Avium Complex (MAC) in a Hollow Fiber Model BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today reported financial results and provided an update on corporate activities for the quarter ended March 31, 2022. “Our commercial execution continue
- GlobeNewswire
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on April 29, 2022, the Company granted stock options to one new employee of the Company. This award was granted pursuant to the Paratek Pharmaceuticals, Inc. 2017
